The battle between U.K. authorities and Vertex (VRTX) Pharmaceuticals (VRTX) over the cost of its cystic fibrosis medicines took another twist as the drug maker declined to provide information about its newest treatment to a cost-effectiveness watchdog. In doing so, the company is delaying the approval process used to make the new treatment available to patients.

The move is the latest bit of brinkmanship between the drug maker and government officials, who have been haggling for more than two years. And the impasse underscores the rising friction that can occur when cash-strapped governments confront high-priced medicines, an issue that is engulfing a growing number of countries, prompting patients to complain they have become pawns.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • this is ridiculous. Orkambi is clearly a drug that prolongs life for people who respond to it, and improves quality of life as well. Both parties have culpability here. And patients are left dangling. Let’s get this done people!

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy